Neximmune reports fourth quarter and full year 2022 financial results and provides business updates

Gaithersburg, md., march 28, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells for liquid and solid malignancies, today reported financial results for the fourth quarter and full year 2022.
NEXI Ratings Summary
NEXI Quant Ranking